Randomized Comparison of Upstream Tirofiban Versus Downstream High Bolus Dose Tirofiban or Abciximab on Tissue-Level Perfusion and Troponin Release in High-Risk Acute Coronary Syndromes Treated With Percutaneous Coronary Interventions The EVEREST Trial by Bolognese, Leonardo et al.
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OBJECTIVES We aimed to compare the effects of upstream tirofiban versus downstream high-dose bolus
(HDB) tirofiban and abciximab on tissue level perfusion and troponin I release in high-risk
non–ST-segment elevation acute coronary syndrome (ACS) patients treated with percuta-
neous coronary intervention (PCI).
BACKGROUND Optimal timing and dosage of glycoprotein IIb/IIIa inhibitors for ACS remain to be
explored.
METHODS We randomized 93 high-risk ACS patients undergoing PCI to receive upstream (in the
coronary care unit) tirofiban, downstream (just prior to PCI) HDB tirofiban, and downstream
abciximab. We evaluated the effects of the three drug regimens on tissue-level perfusion using
the corrected Thrombolysis In Myocardial Infarction (TIMI) frame count, the TIMI
myocardial perfusion grade (TMPG), and intracoronary myocardial contrast echocardiogra-
phy (MCE) before and immediately after PCI and after cardiac troponin I (cTnI).
RESULTS The TMPG 0/1 perfusion was significantly less frequent with upstream tirofiban compared
with HDB tirofiban and abciximab both before (28.1% vs. 66.7% vs. 71%, respectively; p 
0.0009) and after PCI (6.2% vs. 20% vs. 35.5%, respectively; p 0.015). Upstream tirofiban was
also associated with a significantly higher MCE score index (0.88 0.18 vs. 0.77 0.32 vs. 0.71
 0.30, respectively; p 0.05). Post-procedural cTnI elevation was significantly less frequent
among patients in the upstream tirofiban group compared with the HDB tirofiban and
abciximab groups (9.4% vs. 30% vs. 38.7%, respectively; p  0.018). The cTnI levels after
PCI were significantly lower with upstream tirofiban compared with HDB tirofiban (3.8 
4.1 vs. 7.2  12; p  0.015) and abciximab (3.8  4.1 vs. 9  13.8; p  0.0002)
CONCLUSIONS Among high-risk non–ST-segment-elevation ACS patients treated with an early invasive
strategy, upstream tirofiban is associated with improved tissue-level perfusion and attenuated
myocardial damage. (J Am Coll Cardiol 2006;47:522–8) © 2006 by the American College
ublished by Elsevier Inc. doi:10.1016/j.jacc.2005.11.012of Cardiology Foundation
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rhe most recent guidelines for the management of patients
resenting with a non–ST-segment-elevation acute coro-
ary syndrome (NSTE-ACS) strongly recommend the use
f glycoprotein (GP) IIb/IIIa receptor antagonists for high-
See page 538
isk patients when percutaneous coronary intervention
PCI) is planned (1,2). Although several randomized trials
ith different GP IIb/IIIa antagonists have convincingly
emonstrated the usefulness of this therapeutic strategy, a
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005, accepted February 8, 2005.umber of lingering unsolved issues concerning which
gent should be used and the most appropriate timing
nd dosage remain to be explored. Patients with ACS
ay have decreased response to antiplatelet agents (3),
nd tirofiban may be less effective than abciximab within
0 min after administration (4). Recently, Schneider et
l. (5) have identified a tirofiban bolus of 25 g/kg
followed by maintenance infusion of 0.15 g/kg/min)
hat achieves inhibition of platelet aggregation 85%
hrough 60 min. Preliminary reports have documented
afety and efficacy of this dose regimen in patients
ndergoing elective or high-risk PCI (6,7). The role of
his regimen in high-risk patients with NSTE-ACS
emains to be established. Furthermore, there is uncer-
ainty about whether GP IIb/IIIa inhibitors should be
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February 7, 2006:522–8 GP IIb/IIIa Inhibitors and Post-PCI Perfusion in ACSiven just before PCI if an early (within 48 h) invasive
trategy is planned in this setting.
We sought to compare the effects of upstream tirofiban
ersus downstream high-dose bolus (HDB) tirofiban or
bciximab on epicardial and tissue-level perfusion and
ardiac troponin I (cTnI) release in high-risk NSTE-ACS
reated with PCI. We hypothesized that patients who were
reated with upstream tirofiban regimen would have a better
issue-level perfusion and reduced cTnI release after inter-
entions than patients who were treated with downstream
DB tirofiban or abciximab. We also hypothesized that no
ignificant difference would be found between the down-
tream HDB tirofiban and abciximab regimens.
ETHODS
atients and study protocol. Between September 2003
nd July 2004, 93 patients were enrolled in a single-center
pen-label randomized study. Patients were selected from
61 patients consecutively referred to our coronary care unit
CCU) for angina at rest. Patients were considered eligible
or the enrolment if they fulfilled all of the following
riteria: 1) angina at rest lasting 10 min within 12 h of
ospital admission; 2) unequivocal changes on ECG during
ngina; and 3) cTnI elevation. No upper age limit was used.
ll patients were required to undergo coronary angiography
ithin 24 to 48 h of admission, with revascularization with
CI as appropriate. Exclusion criteria were: 1) inability to
rovide informed consent; 2) any relative or absolute con-
raindication to platelet GP IIb/IIIa inhibition; 3) concom-
tant noncardiac life-threatening disease; 4) severe hemody-
amic impairment or cardiogenic shock; and 5) significant
Abbreviations and Acronyms
ACS  acute coronary syndrome
CAD  coronary artery disease
CCU  coronary care unit
cTFC  corrected TIMI frame count
cTnI  cardiac troponin I
GP  glycoprotein
HDB  high-dose bolus
MCE  myocardial contrast
echocardiography
NSTE-ACS  non–ST-segment-elevation acute
coronary syndrome
PCI  percutaneous coronary
intervention
TACTICS-TIMI 18  Treat Angina with Aggrastat
and Determine Cost of Therapy
with an Invasive or Conservative
Strategy-Thrombolysis In
Myocardial Infarction 18
TIMI  Thrombolysis In Myocardial
Infarction
TMPG  TIMI myocardial perfusion
gradether cardiac disease. iPatients were randomized to the three following treat-
ent arms: CCU (upstream) tirofiban administration as a
olus dose of 0.4 g/kg/min for a period of 30 min,
ollowed by an infusion of 0.10 g/kg/min up to 12 h after
CI; “in-cath lab” (downstream) high-dose bolus (HDB)
irofiban of 25 g/kg per 3 min, 10 min before PCI,
ollowed by an infusion of 0.15 g/kg/min for 12 h; and
in-cath lab” (downstream) abciximab bolus of 0.25 mg/kg
0 min before PCI, followed by 0.125 g/kg for 12 h to a
aximum of 10 g/min. Of the 161 patients initially
elected for the study, 131 were randomized, but 28 were
xcluded at the time of coronary angiography because of
hree-vessel coronary artery disease (CAD) requiring coro-
ary artery bypass grafting (10 in the upstream tirofiban
roup, 9 in the HDB tirofiban group, and 9 in the
bciximab group) and 10 for the absence of significant CAD
t the angiogram or lesions not suitable for PCI (3 in the
pstream tirofiban group, 3 in the HDB tirofiban group,
nd 4 in the abciximab group). Even if not enrolled in the
tudy, these patients were entered into a registry and
ollowed up for cardiac events and bleeding complications
or at least 30 days. Thus, 93 patients (70 men, 23 women;
ean age 64.8  11.2 years; range 35 to 83 years) represent
he final study group.
All patients underwent PCI within 24 to 48 h of
dmission. Angiographic markers of epicardial flow and
issue-level perfusion were assessed on completion of diag-
ostic coronary angiography and shortly after PCI. Intra-
oronary myocardial contrast echocardiography (MCE) was
erformed on completion of PCI. Blood samples for cTnI
evels were obtained on admission and every 6 h thereafter
p to 48 h and at 6, 12, 18, and 24 h after PCI.
The study protocol was approved by the hospital’s ethics
ommittee, and written informed consent was obtained
rom all patients before catheterization.
roponin testing. cTnI was measured using the commer-
ially available Dimension RxL immunoassay (Dade-
ehring Ltd., Milton Keynes, United Kingdom). The
anufacturer reports the minimum detectable concentra-
ion as 0.01 ng/ml. The total imprecision determined in the
aboratory was characterized by a coefficient of variation of
0% at 0.05 ng/ml. The threshold used to define a positive
TnI was 0.1 ng/ml. A post-procedural elevation in cTnI
as defined as an increase by 50% above the highest
reprocedural value in at least one of the post-procedural
amples.
CI, concomitant drugs, and angiographic analysis. Coro-
ary angioplasty and stent implantation were performed
ccording to institutional standards. All patients received
spirin (100 to 300 mg) before and after PCI. Ticlopidine
500 mg) or clopidogrel (300 mg loading dose, followed by
5 mg/day) was administered before PCI and daily there-
fter for at least 30 days.
All coronary angiograms were evaluated by two readers
ithout knowledge of clinical status and treatment modal-
ty. Flow in the epicardial arteries was assessed for Throm-
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GP IIb/IIIa Inhibitors and Post-PCI Perfusion in ACS February 7, 2006:522–8olysis In Myocardial Infarction (TIMI) flow grade and
orrected TIMI frame count (cTFC) by use of previously
escribed methods (8,9). The TIMI myocardial perfusion
rade (TMPG) was used to assess myocardial tissue-level
erfusion (10). A “closed” microvasculature was defined as
ither TMPG 0 or 1, with TMPG 2 or 3 representative of
n “open” microvasculature (10). TMPG was assessed only
n the area supplied by the culprit vessel.
yocardial contrast echocardiography. Intracoronary
CE was performed on completion of coronary angio-
lasty. A score of 1 within a segment of the area of interest
fter angioplasty was interpreted as adequate perfusion. A
atient was considered to have adequate perfusion if
50% of the segments in the area of interest had a
omogeneous contrast effect (score  1). In each patient,
n MCE score index was derived. Details pertaining to
cquisition and analyses of echocardiographic data are
vailable elsewhere (11).
leeding complications. Major bleeding was defined as a
all in hemoglobin of 2.0 mmol/l and the need for
ransfusion of 2 U of blood, corrective groin surgery, or
oth, or as bleeding that resulted in documented intracra-
ial, gastrointestinal, or retroperitoneal hemorrhage. Minor
leeding was defined as a fall in hemoglobin of2.0 mmol/l
ithout the need for a transfusion (12).
tatistical analysis. The primary end point of the study
as the difference in the TMPG before PCI. Assuming a
0% lower TMPG 0/1 rate in the upstream tirofiban group
ompared with HDB tirofiban and abciximab groups, we
stimated that 90 patients would provide 80% statistical
ower (1   0.80;   0.05) to detect such difference.
he secondary end points were evaluations of TIMI grade
ow, cTFC, and TMPG before and after PCI, and MCE
ontrast enhancement and cTnI release after PCI in the
hree groups. Continuous data are expressed as mean values
able 1. Baseline Clinical Characteristics
All Upstrea
o. of patients 93
TnI pre-PCI
Mean  SD 5.38  6.39 6.5
Median 3.3
ge (yrs) 64.8  11.2 61.9
ale gender, n (%) 70 (75.3) 27
amily history of CAD, n (%) 26 (28) 9
mokers, n (%) 31 (33) 15
ypertension, n (%) 56 (60.2) 20
iabetes, n (%) 23 (23.9) 13
yslipidemia, n (%) 41 (44) 11
revious AMI, n (%) 16 (17.2) 3
nterior location, n (%) 48 (50) 16
lopidogrel, n (%) 69 (74.1) 25
T-segment depression, n (%) 54 (58) 19
-wave inversion, n (%) 39 (41.9) 13
ime to coronary angioplasty (h) 27.2  15.1 30.4Upstream tirofiban vs. HDB tirofiban, p  0.023.
AMI  acute myocardial infarction; CAD  coronary artery disease; cTnI  cardiac tSD. Analysis of variance was used to compare continuous
ariables and Fisher exact tests for categorical variables.
A value of p  0.05 was considered statistically signifi-
ant. Statistical analyses were performed with SPSS 8.0 for
indows (SPSS Inc., Chicago, Illinois).
ESULTS
n the 131 randomized patients, drug infusion was discon-
inued in advance in 4 patients in the upstream tirofiban, in
in the HDB tirofiban, and in 3 in the abciximab group,
ainly for groin hematoma. Minor bleeding was observed
n 5, 4, and 5 patients, respectively. Major bleeding due to
astrointestinal hemorrhage occurred in 1 patient (abcix-
mab group). Of note, of the 13 patients randomized to
pstream tirofiban but not enrolled to the study, 2 had just
inor bleeding; no major bleeding was observed in the 10
atients who required urgent CABG.
Clinical characteristics of the 93 patients enrolled in the
tudy stratified according to the treatment modality are
ummarized in Table 1. The incidence of diabetes mellitus
as significantly higher in the upstream tirofiban group
han in the other two groups. No other statistically signif-
cant differences in the baseline distribution of clinical and
emographic characteristics between groups were found.
verall, 69 patients received clopidogrel; no significant
ifference was observed in the clopidogrel usage between
roups (78% in the upstream tirofiban, 77% in the down-
tream HDB tirofiban, and 68% in the downstream abcix-
mab group).
ngiographic findings and treatment modality. Overall,
7 patients (50%) had a TIMI flow grade of 0 to 2, and 51
55%) had a closed microvasculature as assessed by TMPG
0/1) before PCI. All patients underwent successful PCI
ith a TIMI flow grade of 3 after the procedure. Of the
1 patients with TMPG 0/1 before PCI, 32 had a
ofiban HBD Tirofiban Abciximab p
30 31
8 4.5  5.7 5.1  6.6 NS
3.02 2.03
.8 59.7  11.8 66.8  10.6 NS
) 19 (63.3) 24 (77.4) NS
) 10 (33.3) 7 (22.6) NS
) 8 (26.7) 8 (25.8) NS
) 16 (53.3) 20 (64.5) NS
) 4 (13.3) 6 (19.4) 0.023*
) 16 (53.3) 14 (45.2) NS
4 (13.3) 9 (29) NS
17 (56.7) 15 (48.4) NS
23 (76.7) 21 (67.7) NS
) 18 (60) 17 (54.8) NS
12 (40) 14 (45.2) NS
.6 26.0  12.4 26.1  18.7 NSm Tir
32
 6.
4.8
 14
(84.4
(28.1
(46.9
(62.5
(40.6
(34.4
(9.4)
(50)
(78)
(59.4
(40)
 13roponin I; HDB  high-dose bolus; PCI  percutaneous coronary intervention.
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February 7, 2006:522–8 GP IIb/IIIa Inhibitors and Post-PCI Perfusion in ACSMPG of 2/3 after PCI. No patient with an open
icrovasculature before PCI (TMPG 2/3) had a closed
icrovasculature after PCI (TMPG 0/1). No significant
ifference in TMPG 2/3 perfusion was observed between
lopidogrel and ticlopidine treatment both before and
fter PCI (46% vs. 44% before PCI, and 78% vs. 84%
fter PCI, respectively; p  NS).
There was no significant difference in the distribution of
he culprit lesion, the frequency of angiographic thrombus,
he angiographic morphology of the culprit lesion, the
xtent of CAD, and pre- and post-PCI TIMI grade flow,
TFC, and cTFC between groups (Table 2).
Before PCI, TMPG 0/1 perfusion was significantly less
requent with upstream tirofiban than with HDB tirofiban
able 2. Angiographic Characteristics
All Ups
o. of patients 93
VD pre-PCI (mm) 2.98  0.42
LD pre-PCI (mm) 0.10  0.14
LD post-PCI (mm) 3.0  0.41
esion length (mm) 12.1  4.68
esion type A 4 (4)
esion type B1 49 (52.6)
esion type B2 40 (43)
hrombus, n (%) 43 (46.2)
IMI flow grade 2/3 pre-PCI, n (%) 76 (81.7)
IMI flow grade 3 post-PCI, n (%) 93 (100)
IMI frame count pre-PCI (frames) 31.6  17.3
IMI frame count post-PCI (frames) 17.8  7.11
TIMI frame count 0.43  0.23
ultivessel disease, n (%) 32 (34.4)
ulprit vessel stenosis (%) 96.6  4.5
AD, n (%) 41 (44)
X, n (%) 29 (31.1)
CA, n (%) 23 (24.7)
X  circumflex coronary artery; HBD  high-dose bolus; LAD  left anterior desc
VD  culprit reference vessel diameter; TIMI  Thrombolysis In Myocardial Inf
igure 1. Rate of Thrombolysis In Myocardial Infarction myocardial pe
reatment pre-percutaneous coronary intervention (PCI) (A) and post-PCI (B)
HDB) vs. abciximab before PCI. p  0.015 by Fisher exact test upstream tirond abciximab (28.1% vs. 66.7% vs. 71%, respectively; p 
.0009 by Fisher exact test) (Fig. 1A). Also after PCI,
MPG 0/1 perfusion was observed less frequently with
pstream tirofiban compared with HDB tirofiban and
bciximab (6.2% vs. 20% vs. 35.5%, respectively; p 0.015)
Fig. 1B). No significant difference was found in terms of
re- and post-PCI TMPG perfusion between the HDB
irofiban and abciximab regimens.
erfusion by MCE and treatment modality. Intracoro-
ary MCE analysis was performed in 83 patients (26 of the
pstream tirofiban, 28 of the HDB tirofiban, and 29 of the
bciximab group), because 10 were excluded owing to
nadequate image quality. Intracoronary MCE was evalu-
ted in a total of 249 segments; of these, 178 (71.5%) showed
Tirofiban HBD Tirofiban Abciximab p
2 30 31
 0.47 2.93  0.42 2.92  0.35 NS
 0.16 0.13  0.17 0.08  0.1 NS
 0.48 2.94  0.42 2.96  0.33 NS
 3.5 11.7  5 12.4  5.47 NS
3.1) 2 (6.7) 1 (3.2) NS
62.5) 12 (40) 17 (54.9) NS
34.4) 16 (53.3) 13 (41.9) NS
37.5) 14 (46.7) 17 (55) NS
87.5) 24 (80) 24 (77.4) NS
100) 30 (100) 31 (100) NS
 13 28.9  16 37.5  21.6 NS
 7.5 15.8  6.5 18.8  7.1 NS
 0.19 0.45  0.23 0.49  0.25 NS
28.1) 12 (40) 11 (36.7) NS
 3.1 95.6  4.7 97.3  5.3 NS
40.6) 15 (50) 13 (41.9) NS
25) 11 (36.7) 10 (32.3) NS
34.4) 4 (13.3) 8 (25.8) NS
g coronary artery; MLD  minimal luminal diameter; RCA  right coronary artery;
.
n grade (TMPG) 0/1 flow stratified by glycoprotein IIb/IIIa inhibitortream
3
3.07
0.11
3.1
12.3
1 (
20 (
11 (
12 (
28 (
32 (
28.9
18.8
0.39
9 (
96.4
13 (
8 (
11 (rfusio
. p  0.0009 by Fisher exact test upstream tirofiban vs. high-dose bolus
fiban vs. HDB vs. abciximab after PCI.
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GP IIb/IIIa Inhibitors and Post-PCI Perfusion in ACS February 7, 2006:522–8omogeneous contrast effect (score  1). A trend toward a
igher number of perfused segments (score 1) was observed
ith upstream tirofiban compared with HDB tirofiban and
bciximab, but it did not reach a statistical significance (78.2%
s. 70.2% vs 66.7%; p  0.6). MCE score index was signifi-
antly higher with upstream tirofiban than withHDB tirofiban
nd abciximab (0.87  0.19 vs. 0.77  0.32 vs. 0.71  0.35,
espectively; p 0.05 by analysis of variance [ANOVA]) (Fig.
A). Analysis by patient showed that patients treated with the
pstream tirofiban more frequently had a normal tissue-level
erfusion by MCE than those treated with HDB tirofiban or
bciximab (96.2% vs. 75% vs. 72.4%, respectively; p  0.04)
Fig. 2B).
roponin I release. By design, all patients had elevated
reprocedural cTnI levels. No significant difference in peak
re-PCI cTnI levels was found between groups (6.5 6.8 for
pstream tirofiban regimen vs. 4.5 5.7 for HDB tirofiban vs.
.0  6.6 for abciximab; p  0.45 by ANOVA).
Twenty-four patients (26%) had a post-procedural cTnI
levation that was significantly less frequent among patients
n the upstream tirofiban group compared with the HDB
irofiban and abciximab groups (9.4% vs. 30% vs. 38.7,
espectively; p  0.018).
Quantitatively, cTnI levels after PCI were significantly
ower with upstream tirofiban than with HDB tirofiban (3.8
.1 vs. 7.2 12; p 0.015) and abciximab (3.8 4.1 vs. 9
3.8; p  0.0002).
ISCUSSION
his pilot study shows that in high-risk NSTE-ACS
reated with early PCI, an upstream tirofiban regimen is
ssociated with better tissue-level perfusion, both before and
fter intervention, and less post-procedural cTnI release
ompared with downstream HDB tirofiban and abciximab.
igure 2. (A) Myocardial contrast echocardiography score index (MCSEI)
atients. p  0.05 by analysis of variance (ANOVA) upstream tirofiba
yocardial contrast echocardiography (MCE) among the three therapeu
bciximab.n the other hand, no significant difference was found on rissue-level perfusion and cTnI release between downstream
DB tirofiban and abciximab.
pstream versus downstream GP IIb/IIIa inhibitors. The
ontribution of GP IIb/IIIa inhibition in NSTE-ACS is
hown in placebo-controlled trials in which upstream GP
Ib/IIIa inhibition was initiated upon admission (13). Al-
hough these results are encouraging, there are few other
ata to support the use of upstream GP IIb/IIIa inhibitors
14). In the Treat Angina with Aggrastat and Determine
ost of Therapy with an Invasive or Conservative Strategy-
hrombolysis In Myocardial Infarction 18 (TACTICS-
IMI 18) trial (15), all patients received upstream GP
Ib/IIIa inhibitors and were randomized to either early
nvasive or conservative treatment, so the design did not
ermit a definitive statement to be made as to whether
pstream GP IIb/IIIa inhibition is helpful in patients who
rogress to an early invasive strategy. Also, there has been
o randomized trial in which patients were actually ran-
omized to receive upstream or downstream GP IIb/IIIa
nhibitors. To our knowledge, the present pilot study is the
rst experience comparing in a randomized manner up-
tream versus downstream GP IIb/IIIa inhibitors in the
etting of an early invasive strategy for high-risk NSTE-
CS. The results show that patients treated with upstream
irofiban had improved pre- and post-PCI tissue level
erfusion and attenuation of myocardial damage. These
echanistic findings confirm and expand previous experi-
ental data (16) and coupled with the clinical findings from
he TACTICS-TIMI 18 trial (15,17) suggest that the
arlier initiation of tirofiban for patients with NSTE-ACS,
ollowed by routine angiography within 48 h and PCI as
ppropriate, may yield more favorable outcomes.
iming and dosage of GP IIb/IIIa inhibitors. The pre-
umed benefits of early therapy with GP IIb/IIIa inhibitors
semiquantitative index of impaired tissue perfusion in the three groups of
us high-dose bolus (HDB) versus abciximab. (B) Patients perfused by
gimen groups. p  0.04 by ANOVA upstream tirofiban vs. HDB vs.as a
n vers
tic reaise the question of whether there are differences among
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February 7, 2006:522–8 GP IIb/IIIa Inhibitors and Post-PCI Perfusion in ACShe available agents. The Tirofiban and Reopro Give Sim-
lar Efficacy Outcomes Trial (TARGET) (18) demon-
trated the superiority of PCI in combination with abcix-
mab instead of tirofiban at 30 days. The reasons for these
esults are currently speculative and possibly due to an
nadequate early platelet inhibition with tirofiban in the
ARGET regimen. In a randomized comparison of platelet
nhibition with abciximab, tirofiban, and eptifibatide during
CI in the ACS (19), platelet aggregation 15 and 30 min
fter drug infusion was significantly less inhibited with the
irofiban-TARGET regimen compared with abciximab and
ptifibatide. Therefore, the two-compartment model of
reating ACS patients (20)—“upstream” versus “down-
tream”—might only remain separated by the adequacy of
ime allowed for steady-state concentrations in plasma of
mall-molecule agents to be reached before PCI. Thus, a
ossible way to remove the compartmentation might be
ith an adequately high-dose bolus of tirofiban to maintain
t least 90% inhibition of platelet aggregation until steady
tate is reached with the infusion. Although preliminary
eports have documented safety and efficacy of this dose
egimen in patients undergoing elective or high-risk PCI
6,7), its role in NSTE-ACS remains to be addressed. In
he present study, upstream tirofiban was associated with a
etter angiographic outcome than HDB tirofiban, suggest-
ng that early treatment in CCU is better than a high dosage
n the catheterization laboratory for achieving an improve-
ent in tissue-level reperfusion and attenuation of myo-
ardial damage. On the other hand, we also found no
ignificant difference in angiographic outcome and post-
rocedural cTnI release between downstream HDB tiro-
ban and abciximab. These findings confirm and expand
ecent observations showing similar effects of HDB tirofi-
an and abciximab on the extent of platelet inhibition as
ell as on angiographic outcome and left ventricular func-
ion recovery in ST-segment elevation ACS (12,21).
tudy limitations. Although timing of coronary angiogra-
hy and PCI was similar between groups (within 48 h of
dmission), the beneficial effects of upstream tirofiban in the
resent study might partly depend on the delay itself,
ecause downstream groups did not receive GP IIb/IIIa
nhibitors until PCI was performed. Further studies com-
aring early (within 48 h) invasive strategy with upstream
P IIb/IIIa inhibitor treatment with fast-track (within a
ew hours) invasive strategy with downstream treatment are
eeded to resolve this issue.
The effects of the different drug regimens on the extent of
latelet inhibition were not investigated. Such data might
ave provided additional insights into the relationship
etween the degree of platelet inhibition and perfusion and
nzymatic outcome.
onclusions. This pilot study shows that in high-risk
STE-ACS, an early invasive strategy with upstream tiro-
ban is associated with improved tissue-level perfusion and
ttenuated myocardial damage, compared with an early inva-
ive strategy with downstream HDB tirofiban or abciximab.
1igh-dose bolus tirofiban or abciximab administered just
efore PCI achieved similar effects on angiographic outcome
nd cTnI release. Further studies are needed to clarify if the
trategy and dose regimens have a clinical impact.
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